Stockholm, January 11th 2024. Capitainer, a leading Swedish medtech innovator specializing in advanced self-sampling solutions, is proud to announce the grant of three US patents for their soon to be launched plasma/serum separation device. These patents cover the company’s technology for automatic separation and metering from whole blood. The company has an expected patent protection until 2042.
The United States Patent and Trademark Office (USPTO) has granted Capitainer three patents related to their plasma/serum separation device, Capitainer®SEP10. The patents cover the developed microfluidic solutions that enable patients to sample at home without any more demands than applying fresh finger blood to the card. The patents ensure that Capitainer’s technology is patent-protected in the US until at least 2042. Additionally, there are several patent applications currently pending in various markets around the world.
“Our solution is unique on the market, having solved the technical challenges that enable whole blood separation of cells from plasma/serum. While the patient engages in the initial step of pricking their finger and applying the blood to the card, our technology then takes over. It automates the subsequent processes of separation and precise volume measurement,” says Anna Ohlander, R&D Manager at Capitainer. “This solution aligns with the overall characteristics of the Capitainer sampling platform to make it easy to sample accurately with quality for clinical diagnostics.”
“These patents reinforce our strategic position, facilitating Capitainer’s expansion in the US market. The recognition from the United States Patent Office is a testament to the technological advancements we’ve achieved. This enables us to extend our advanced solutions to a broader range of healthcare providers and researchers,” says Christopher Aulin, CEO at Capitainer.
With the North America blood testing market size being estimated to reach USD 43.4 billion by 2032, the United States constitutes one of the largest potential commercial opportunities for Capitainer. Capitainer’s technology is protected by a broad patent portfolio in major geographic markets, and the strategy is to continually seek patents for new innovations. The company currently has six patent families. With the world’s major markets covered, Capitainer is ready to continue its growth and expansion, offering its advanced solutions to healthcare providers and researchers globally.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Capitainer AB is a Swedish medtech company founded in 2016. Capitainer develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed unique technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples are market-leading and perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies.